Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter |
| Thursday, 28 January 2010 |
|
|
Friday, February 5, 2010
Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter
Worldwide sales increased 10.6 percent to nearly $8.8 billion, including a favorable 2.4 percent effect of exchange rates. Excluding the expected decline in Depakote(R) sales due to generic competition, worldwide reported sales increased 12.7 percent. Full-year 2009 sales were $30.8 billion. 
New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas
New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas |
| Thursday, 28 January 2010 |
|
|
Pfizer Inc. has provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development. AstraZeneca Fourth Quarter and Full Year Results 2009
AstraZeneca Fourth Quarter and Full Year Results 2009 |
| Friday, 29 January 2010 |
|
|
Revenue in the fourth quarter increased by 4 percent at constant exchange rates (CER), but was up 9 percent on an actual basis as a result of the positive impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); Digital Pharma Europe at Bayer Schering Pharma Headquarters Berlin
Digital Pharma Europe at Bayer Schering Pharma Headquarters Berlin |
| Friday, 29 January 2010 |
| 29-30 March 2010, Bayer Schering Pharma Headquarters Berlin, Germany. |
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
| Lilly Reports Fourth-Quarter and Full-Year 2009 Results |
| Monday, 01 February 2010 |
|
|
In the fourth quarter of 2009, worldwide total revenue was $5.934 billion, an increase of 14 percent compared with the fourth quarter of 2008. This 14 percent revenue growth was comprised of an increase of 7 percent due to higher volume, 3 percent due to higher prices, and 3 percent due to the impact of foreign exchange rates (numbers do not add due to rounding). Roche establishes new medical research hub in Singapore
Roche establishes new medical research hub in Singapore |
| Monday, 01 February 2010 |
|
|
Roche (SIX: RO, ROG; OTCQX: RHHBY) will enter into a strategic alliance with Singapore's scientific and medical institutions to set up a major new translational research hub in Singapore. This "Hub for Translational Medicine" aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients. VYVANSE® - new ADHD treatment option - now available in Canada
VYVANSE® - new ADHD treatment option - now available in Canada |
| Tuesday, 02 February 2010 |
|
|
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
Subscribe to:
Posts (Atom)
